Vor Systems | $3,000,000 | (Mar 6, 2026)
IntelliGRC | $3,500,000 | (Mar 6, 2026)
Cyclops | $8,000,000 | (Mar 6, 2026)
Receptor Life Sciences, Inc.
United States
- Seattle, Washington
- 07/04/2022
- Series A
- $9,700,000
Receptor Life Sciences combines proven drug delivery technologies, compelling therapeutic candidates, and traditional drug development research practices to pursue a robust range of prescription drug treatments for CNS indications.
The delivery technologies, used in both oral and inhaled FDA-approved prescription drug products, represent a validated, strategic approach to overcoming traditional challenges of cannabinoid medicine. Receptor’s patented product candidates hold the potential to provide prescription treatments for a range of unmet medical needs, including anxiety and agitation in autism.
More information is at www.ReceptorLife.com.
- Industry Pharmaceutical Manufacturing
- Website https://receptorlife.com/
- LinkedIn https://www.linkedin.com/company/receptor-life-sciences-inc./
Related People
Mark TheeuwesFounder
United States -
Greater Philadelphia
Experienced Pharmaceutical Executive with a demonstrated history of working in all aspects of Clinical and Commercial Execution.
Lio (formerly askLio) | $30,000,000 | (Mar 6, 2026)
Navigara | $2,500,000 | (Mar 6, 2026)
AgriPass | $7,500,000 | (Mar 6, 2026)
Reclaim Security | $20,000,000 | (Mar 6, 2026)
NextWork | $4,450,000 | (Mar 6, 2026)
Vast | $500,000,000 | (Mar 6, 2026)
Qura | $1,739,595 | (Mar 4, 2026)
Escargot | $2,750,000 | (Mar 4, 2026)
Worldscape | Undisclosed Amount | (Mar 4, 2026)